Gibson Dunn Advises Arrowhead Pharmaceuticals on Global Licensing and Collaboration Agreement with Novartis
Firm News | September 4, 2025
Gibson Dunn is advising Arrowhead Pharmaceuticals on its global licensing and collaboration agreement with Novartis for ARO-SNCA, Arrowhead’s preclinical-stage siRNA therapy targeting alpha-synuclein for the treatment of synucleinopathies, as well as for additional collaboration targets utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiM™) platform.
Arrowhead will receive $200 million as an upfront payment and is eligible to receive up to $2 billion in potential milestone payments, plus royalties on commercial sales.
Our Life Sciences team is led by partners Karen Spindler and Ryan Murr and includes partners Pamela Lawrence Endreny, Benjamin Fryer, and Sophia Hansell, along with associates Michael Dziuban, Ryan Rott, and Anna Searcey.